Re: Shedding light on polypragmasy of pain after transurethral prostate surgery procedures: a systematic review and meta-analysis

Abstract

Persistent dysuria, pelvic pain or prostatodynia after transurethral prostate surgery is a classical example of a well recognised but poorly documented urological condition. Clinical presentation can be variable but the symptomatology is somewhat similar to the chronic pelvic pain syndrome [1, 2]. The pain is usually bothersome and it tends to be persistent and refractory to medications. On the other hand, the etiology and pathophysiology are totally different, and the pain always occurs after transurethral prostate surgery. We believe its characteristics are clear and distinct enough to define it as the post-operative pelvic pain syndrome (PPPS). Recently, we conducted a five-question survey to investigate the real world practice of managing PPPS after transurethral prostate surgery. The five questions covered the (1) current position of the respondent, (2) choice of treatment modality for patients with PPPS after transurethral prostate surgery, (3) choice of anti-inflammatory medications for patients with PPPS after transurethral prostate surgery, (4) duration of treatment before being determined ineffective, and (5) treatment response based on a scale of 0–10, i.e., Out of ten patients, how many would actually respond to the treatment. The survey was primarily distributed via the #UroSoMe Twitter platform [3]. A tweet about prolonged pain after transurethral prostate surgery was posted together with a link which directed to the Google Form survey platform. The survey was launched on 4th October 2020 and lasted for 6 weeks. A total of 230 responses were received when the survey was concluded. Among the 230 respondents, 80.0% were urology consultants, 9.6% were urology fellows and 10.4% were urology residents in training. Regarding the choice of treatment modality (Table 1), the majority would offer anti-inflammatory agents (88.7%), followed by alphablocker (42.2%), gabapentin/pregabalin (40.4%) and pelvic physiotherapy (39.6%). For the choice of anti-inflammatory agents, the majority would offer oral non-steroidal and anti-inflammatory drugs (NSAIDs) (81.3%), followed by NSAIDs suppository (17.0%), oral corticosteroids (17.0%) and intramuscular corticosteroids (8.3%). About half of the respondents (49.1%) would try the treatment for 4 weeks before they determine it to be ineffective, but 27.4% would allow a prolonged treatment duration of 8–12 weeks. In their experiences, a mean of 5.9 out of ten patients would respond to the treatment being given. Based on the above survey results, a recommendation on how to manage patients presenting with persistent dysuria/ pelvic pain/prostatodynia after transurethral prostate surgery was developed.